Annexon, Inc.

Annexon, Inc. announced that its President & CEO, Douglas Love, Esq., will participate in fireside chats at two upcoming investor conferences in June 2026. He is scheduled to present at the Jefferies Global Healthcare Conference on June 3 and the Goldman Sachs 47th Annual Global Healthcare Conference on June 9. Live webcasts and replays will be accessible via the company's investor relations website.

Annexon, Inc. announced it has granted inducement equity awards to three new non-executive employees under its 2022 Employment Inducement Award Plan. These awards, approved on May 11, 2026, include options to purchase an aggregate of 243,000 shares of Annexon common stock. The options have an exercise price of $5.21 per share and vest over a four-year period.

Annexon, Inc. reported a net loss of $44.1 million for Q1 2026, a significant improvement from $54.4 million in Q1 2025, primarily driven by a decrease in research and development expenses. The company's cash and short-term investments stood at $225.0 million as of March 31, 2026, and management expects this to fund operations for at least twelve months. Financing activities included raising $32.7 million through its 2024 ATM program and establishing a new $150.0 million 2026 ATM program.

Annexon reported a net loss of $44.1 million, or $0.23 per share, for Q1 2026, an improvement from $54.4 million in Q1 2025. The company highlighted significant pipeline progress, including anticipated topline pivotal Phase 3 data for vonaprument in Geographic Atrophy in Q4 2026. Additionally, an EU MAA for tanruprubart for Guillain-Barré Syndrome is under review, with a BLA submission expected in 2026, and Proof-of-Concept data for ANX1502 is also expected in 2026. Annexon maintains a strong balance sheet with $225 million in cash, providing a runway into H2 2027.

Annexon, Inc. highlighted significant portfolio progress and reported its first quarter 2026 financial results. The company anticipates topline pivotal Phase 3 data for vonaprument in Geographic Atrophy in Q4 2026 and expects to submit a Biologics License Application for tanruprubart in Guillain-Barré Syndrome in 2026. Annexon reported a net loss of $44.1 million for Q1 2026, but maintained a strong balance sheet with approximately $225 million in cash, cash equivalents, and short-term investments, providing an anticipated runway into the second half of 2027.

Annexon, Inc. announced that its President and Chief Executive Officer, Douglas Love, Esq., will present at the Bank of America Securities Health Care Conference 2026. The presentation is scheduled for Wednesday, May 13, 2026, at 11:20 a.m. PT. A live webcast of the event will be accessible via the 'Events & Presentations' section on the Investors page of Annexon's website, with a replay available for 30 days.

Annexon, Inc. filed its definitive proxy statement for the 2026 Annual Meeting of Stockholders, scheduled virtually for June 11, 2026. Key proposals include the election of two Class III directors, ratification of KPMG LLP as the independent auditor, an advisory vote on executive compensation, and a significant proposal to increase the authorized shares of common stock from 300,000,000 to 500,000,000. The Board recommends voting in favor of all proposals.